Skip to main content
SSII
NASDAQ Industrial Applications And Services

SS Innovations Submits FDA Response for SSi Mantra 510(k) — Review Expected Q1 2027

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Medical Device Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$2.55
Mkt Cap
$511.22M
52W Low
$2.5
52W High
$10
52W Position info
2.0% above low
Off High info
75% below high
Rel. Volume info
1.0× avg
Market data snapshot near publication time

SSII is trading near its 52-week low of $2.5 (2.0% above the low).

Summary

SS Innovations submitted its FDA response for the SSi Mantra 510(k) on October 5, 2026, including final clinical and bridging study data. FDA review is expected to complete in Q1 2027.


Key Events · Product Development and Regulatory · SSII

  • FDA Response Submitted

    On October 5, 2026, the company submitted its response to the FDA's request for additional information (AINN) for the SSi Mantra 510(k) application.

  • Clinical Data Included

    The response includes final data from an expanded human clinical and human factors validation study and a bridging study completed in August 2026 at Hospital Internacional de Colombia.

  • FDA Review Timeline

    The company anticipates the FDA will complete its review of the AINN response and 510(k) submission in the first quarter of 2027.

  • Consultant Engaged

    Daniel & Daniel Consulting, LLC was engaged to assist with the AINN response, studies, and 510(k) submission for the initial cholecystectomy indication.


Analysis · SSII · Industrial Applications And Services

SS Innovations has submitted its response to the FDA's request for additional information on the SSi Mantra surgical robotic system's 510(k) application. The response includes final data from an expanded human clinical and human factors validation study plus a bridging study completed in Colombia. This is a critical regulatory milestone for the company's flagship product — FDA clearance would open the U.S. market, the largest surgical robotics market globally. The company expects FDA review to complete in Q1 2027. Against a backdrop of going-concern warnings, material weaknesses, and a recent $20M convertible note with variable-price conversion, this regulatory progress is a meaningful positive development, though the timeline remains uncertain and the company's financial position is fragile.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 37.5% of the 3713 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, SSII was trading at $2.55 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $511.2M. The 52-week trading range was $2.50 to $10.00. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

SSII - Latest Insights

SSII
Nov 13, 2026, 8:56 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.33
Real-time Price: $1.64 info
Change: +$0.310 (+23%) info
Market Cap: $332.794M info
SSII
Oct 13, 2026, 6:05 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $2.55
Real-time Price: $1.64 info
Change: -$0.910 (-36%) info
Market Cap: $332.794M info
SSII
Oct 09, 2026, 5:08 PM EDT
Filing Type: 424B5
Importance Score:
8
Price at Filing: $2.65
Real-time Price: $1.64 info
Change: -$1.01 (-38%) info
Market Cap: $332.794M info
SSII
Sep 17, 2026, 12:21 PM EDT
Source: FinanceWire
Importance Score:
7
Price at Filing: $3.35
Real-time Price: $1.64 info
Change: -$1.71 (-51%) info
Market Cap: $332.794M info
SSII
Sep 10, 2026, 8:30 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $3.22
Real-time Price: $1.64 info
Change: -$1.58 (-49%) info
Market Cap: $332.794M info